Isolated erythrocythemia: A distinct entity or a sub-type of polycythemia vera?

Japanese Journal of Clinical Oncology

Volumn 38, Issue 3, 2008, Pages 230-232

  Ohyashiki, Kazuma ^a   Kiguchi, Toru ^a   Ito, Yoshikazu ^a   Gotoh, Akihiko ^a   Tauchi, Tetsuzo ^a   Miyazawa, Keisuke ^a   Kimura, Yukihiko ^a   Hisatomi, Hisashi ^b   Ohyashiki, Junko H ^b  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b SEIKEI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEMOGLOBIN; JANUS KINASE 2; JAK2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADULT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GENE FREQUENCY; GENE MUTATION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; LEUKOCYTE COUNT; MALE; MYELOFIBROSIS; POLYCYTHEMIA; POLYCYTHEMIA VERA; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOSIS; DIFFERENTIAL DIAGNOSIS; GENETICS; MIDDLE AGED; MUTATION;

DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA;

EID: 40749118909     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym174     Document Type: Letter

References (13)

1. Pierre R, Imbert M, Thiele J, et al. Polycythemia vera. In: Jaffe ES, Harris NL, Stein H, Varidiman JW, editors. World Health Organization of Tumours; Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues, Lyon: IARC Press 2001, 32-4.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-to-care diagnostic algorithms. Leukemia 2008;22:14-22.
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
5. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:779-90.
6. James C, Ugo V, Le Couédic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005;434:1144-5.
7. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788-92.
8. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-68.
9. V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia 2007;21:1097-9.
10. V617F quantification using a magnetic filtration system and sequence-specific primer-single molecule fluorescence detection (SSP-SMFD). Cancer Genet Cytogenet 2007;179:19-24.
11. Verstovsek S, Silver RT, Cross CP, Tefferi A. JAK2V617F mutational frequency in polycythemia vera: 100%,>90%, less? Leukemia 2006;20:2067.
12. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7.
13. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006;20:350-3.